KIT and hepatocellular carcinoma: In 2018, lenvatinib, another TKI targeting VEGFR 1-3, fibroblast growth factor receptor (FGFR) 1-4, PDGFR, RET and KIT (12), was tested as non-inferior to sorafenib in the REFLECT trial and represented an alternative to the latter in the first line treatment of patients with advanced HCC or intermediate HCC refractory to loco-ablative treatments.